Soligenix, Inc. (LON: 0A6I)

Market Cap	5.01M
Revenue (ttm)	271.72K
Net Income (ttm)	-5.30M
Shares Out	n/a
EPS (ttm)	-4.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	661
Average Volume	1,841
Open	2.300
Previous Close	2.330
Day's Range	2.250 - 2.304
52-Week Range	1.550 - 12.516
Beta	n/a
RSI	34.05
Earnings Date	Mar 28, 2025

About Soligenix

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inf...

• Industry: Pharmaceutical Preparations
• Founded: 1987
• Employees: 15
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A6I

Financial Performance

In 2023, Soligenix's revenue was $839,359, a decrease of -11.55% compared to the previous year's $948,911. Losses were -$6.14 million, -55.50% less than in 2022.

Financial numbers in USD